130 related articles for article (PubMed ID: 3265237)
1. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
2. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Burnouf T; Michalski C; Goudemand M; Huart JJ
Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
[TBL] [Abstract][Full Text] [Related]
3. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
[TBL] [Abstract][Full Text] [Related]
4. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
5. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
6. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography.
Feldman PA; Bradbury PI; Williams JD; Sims GE; McPhee JW; Pinnell MA; Harris L; Crombie GI; Evans DR
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930
[TBL] [Abstract][Full Text] [Related]
7. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
Menache D; Behre HE; Orthner CL; Nunez H; Anderson HD; Triantaphyllopoulos DC; Kosow DP
Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
[TBL] [Abstract][Full Text] [Related]
8. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
[TBL] [Abstract][Full Text] [Related]
10. [Technology optimization and properties study of factor IV complex concentrates].
Zeng R; Yu R; Li X; Wu Y; Qi H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):142-4. PubMed ID: 15600207
[TBL] [Abstract][Full Text] [Related]
11. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.
Horowitz B; Bonomo R; Prince AM; Chin SN; Brotman B; Shulman RW
Blood; 1992 Feb; 79(3):826-31. PubMed ID: 1310064
[TBL] [Abstract][Full Text] [Related]
12. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
[TBL] [Abstract][Full Text] [Related]
13. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
Smith KJ
Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
[TBL] [Abstract][Full Text] [Related]
14. The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.
Uszyński L; Poszwiński P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(5):591-4. PubMed ID: 54310
[TBL] [Abstract][Full Text] [Related]
15. Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Mousavi Hosseini K; Nasiri S
Med J Islam Repub Iran; 2015; 29():170. PubMed ID: 26034723
[TBL] [Abstract][Full Text] [Related]
16. Studies of factor IX concentrate therapy in hemophilia.
Hultin MB
Blood; 1983 Sep; 62(3):677-84. PubMed ID: 6603880
[TBL] [Abstract][Full Text] [Related]
17. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
18. Purification of human factor IX by chromatography of a coagulation factor concentrate.
Suomela H
Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of rabbit factor IX and its existence as a two-chain factor IX alpha in circulating plasma.
Rao LV; Hoang AD
Thromb Res; 1991 Oct; 64(1):57-68. PubMed ID: 1776139
[TBL] [Abstract][Full Text] [Related]
20. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
Roberts PL; Dunkerley C
Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
